560 related articles for article (PubMed ID: 31412289)
41. Modified Peptide Inhibitors of the Keap1-Nrf2 Protein-Protein Interaction Incorporating Unnatural Amino Acids.
Georgakopoulos ND; Talapatra SK; Gatliff J; Kozielski F; Wells G
Chembiochem; 2018 Sep; 19(17):1810-1816. PubMed ID: 29927029
[TBL] [Abstract][Full Text] [Related]
42. Prediction of Binding Energy of Keap1 Interaction Motifs in the Nrf2 Antioxidant Pathway and Design of Potential High-Affinity Peptides.
Karttunen M; Choy WY; Cino EA
J Phys Chem B; 2018 Jun; 122(22):5851-5859. PubMed ID: 29745220
[TBL] [Abstract][Full Text] [Related]
43. Structural insights into the multiple binding modes of Dimethyl Fumarate (DMF) and its analogs to the Kelch domain of Keap1.
Unni S; Deshmukh P; Krishnappa G; Kommu P; Padmanabhan B
FEBS J; 2021 Mar; 288(5):1599-1613. PubMed ID: 32672401
[TBL] [Abstract][Full Text] [Related]
44. CPUY192018, a potent inhibitor of the Keap1-Nrf2 protein-protein interaction, alleviates renal inflammation in mice by restricting oxidative stress and NF-κB activation.
Lu MC; Zhao J; Liu YT; Liu T; Tao MM; You QD; Jiang ZY
Redox Biol; 2019 Sep; 26():101266. PubMed ID: 31279986
[TBL] [Abstract][Full Text] [Related]
45. Molecular basis for the disruption of Keap1-Nrf2 interaction via Hinge & Latch mechanism.
Horie Y; Suzuki T; Inoue J; Iso T; Wells G; Moore TW; Mizushima T; Dinkova-Kostova AT; Kasai T; Kamei T; Koshiba S; Yamamoto M
Commun Biol; 2021 May; 4(1):576. PubMed ID: 33990683
[TBL] [Abstract][Full Text] [Related]
46. Emerging Screening Approaches in the Development of Nrf2-Keap1 Protein-Protein Interaction Inhibitors.
Leung CH; Zhang JT; Yang GJ; Liu H; Han QB; Ma DL
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31509940
[TBL] [Abstract][Full Text] [Related]
47. Studies on the bioactivities and molecular mechanism of antioxidant peptides by 3D-QSAR, in vitro evaluation and molecular dynamic simulations.
Yan W; Lin G; Zhang R; Liang Z; Wu W
Food Funct; 2020 Apr; 11(4):3043-3052. PubMed ID: 32190865
[TBL] [Abstract][Full Text] [Related]
48. A systematic molecular dynamics approach to the study of peptide Keap1-Nrf2 protein-protein interaction inhibitors and its application to p62 peptides.
Lu MC; Yuan ZW; Jiang YL; Chen ZY; You QD; Jiang ZY
Mol Biosyst; 2016 Apr; 12(4):1378-87. PubMed ID: 26935067
[TBL] [Abstract][Full Text] [Related]
49. The Keap1-Nrf2-ARE Pathway As a Potential Preventive and Therapeutic Target: An Update.
Lu MC; Ji JA; Jiang ZY; You QD
Med Res Rev; 2016 Sep; 36(5):924-63. PubMed ID: 27192495
[TBL] [Abstract][Full Text] [Related]
50. Acetyl-l-carnitine prevents homocysteine-induced suppression of Nrf2/Keap1 mediated antioxidation in human lens epithelial cells.
Yang SP; Yang XZ; Cao GP
Mol Med Rep; 2015 Jul; 12(1):1145-50. PubMed ID: 25776802
[TBL] [Abstract][Full Text] [Related]
51. Drug-Repositioning Screening for Keap1-Nrf2 Binding Inhibitors using Fluorescence Correlation Spectroscopy.
Yoshizaki Y; Mori T; Ishigami-Yuasa M; Kikuchi E; Takahashi D; Zeniya M; Nomura N; Mori Y; Araki Y; Ando F; Mandai S; Kasagi Y; Arai Y; Sasaki E; Yoshida S; Kagechika H; Rai T; Uchida S; Sohara E
Sci Rep; 2017 Jun; 7(1):3945. PubMed ID: 28638054
[TBL] [Abstract][Full Text] [Related]
52. Involvement of the Keap1-Nrf2-ARE pathway in the antioxidant activity of sinomenine.
Guan T; Li N; Xu X; Xiong D; Wang B; Xiao L; Yang W; Chu G; Yusuf A; Zhang J; Yue W
Arch Biochem Biophys; 2024 Mar; 753():109928. PubMed ID: 38354876
[TBL] [Abstract][Full Text] [Related]
53. Targeting Nrf2-Keap1 signaling for chemoprevention of skin carcinogenesis with bioactive phytochemicals.
Chun KS; Kundu J; Kundu JK; Surh YJ
Toxicol Lett; 2014 Aug; 229(1):73-84. PubMed ID: 24875534
[TBL] [Abstract][Full Text] [Related]
54. Identification of a novel small-molecule Keap1-Nrf2 PPI inhibitor with cytoprotective effects on LPS-induced cardiomyopathy.
Jiang CS; Zhuang CL; Zhu K; Zhang J; Muehlmann LA; Figueiró Longo JP; Azevedo RB; Zhang W; Meng N; Zhang H
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):833-841. PubMed ID: 29693453
[TBL] [Abstract][Full Text] [Related]
55. Deconstructing Noncovalent Kelch-like ECH-Associated Protein 1 (Keap1) Inhibitors into Fragments to Reconstruct New Potent Compounds.
Pallesen JS; Narayanan D; Tran KT; Solbak SMØ; Marseglia G; Sørensen LME; Høj LJ; Munafò F; Carmona RMC; Garcia AD; Desu HL; Brambilla R; Johansen TN; Popowicz GM; Sattler M; Gajhede M; Bach A
J Med Chem; 2021 Apr; 64(8):4623-4661. PubMed ID: 33818106
[TBL] [Abstract][Full Text] [Related]
56. Synthesis, antioxidant,
Siddiqa A; Tajammal A; Irfan A; Munawar MA; Azam M; Basra MAR
J Biomol Struct Dyn; 2022; 40(20):10265-10277. PubMed ID: 34176443
[TBL] [Abstract][Full Text] [Related]
57. Inhibitors of Keap1-Nrf2 protein-protein interaction reduce estrogen responsive gene expression and oxidative stress in estrogen receptor-positive breast cancer.
Xie T; Zahid H; Ali AR; Joyce R; Yang G; Winz C; Le Y; Zhou R; Furmanski P; Hu L; Suh N
Toxicol Appl Pharmacol; 2023 Feb; 460():116375. PubMed ID: 36634873
[TBL] [Abstract][Full Text] [Related]
58. Fragment-growing guided design of Keap1-Nrf2 protein-protein interaction inhibitors for targeting myocarditis.
Meng N; Tang H; Zhang H; Jiang C; Su L; Min X; Zhang W; Zhang H; Miao Z; Zhang W; Zhuang C
Free Radic Biol Med; 2018 Mar; 117():228-237. PubMed ID: 29428410
[TBL] [Abstract][Full Text] [Related]
59. Ginnalin A Binds to the Subpockets of Keap1 Kelch Domain To Activate the Nrf2-Regulated Antioxidant Defense System in SH-SY5Y Cells.
Zhang Z; Peng L; Fu Y; Wang W; Wang P; Zhou F
ACS Chem Neurosci; 2021 Mar; 12(5):872-882. PubMed ID: 33571414
[TBL] [Abstract][Full Text] [Related]
60. Epigallocatechin gallate potentially abrogates fluoride induced lung oxidative stress, inflammation via Nrf2/Keap1 signaling pathway in rats: An in-vivo and in-silico study.
Shanmugam T; Selvaraj M; Poomalai S
Int Immunopharmacol; 2016 Oct; 39():128-139. PubMed ID: 27472294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
